Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

NCT01180322 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01180322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01180322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
October 2, 2016
Enrollment
277 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)